PHILADELPHIA — The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with a significant decrease in the risk for early-onset colorectal cancer (EO-CRC) in patients with type 2 ...

Semaglutide reduced colorectal cancer risk among people with inflammatory bowel disease (IBD), as well as those with both IBD ...

Colorectal cancer is recognized as the fourth most prevalent malignant neoplasm and the third primary driver of cancer mortality across the globe 1. Approximately 20% of colorectal cancers (CRCs) are ...

Good day, and thank you for standing by. Welcome to the Cardiff Oncology Inc. Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to ...

Cardiff Oncology completed patient enrollment in the Phase 2 CRDF-004 trial for RAS-mutated mCRC, with data expected in 2025. Cardiff Oncology, Inc. announced the completion of patient enrollment in ...

A, Boxplots showing the duration of draping, patient positioning, trocar placement, and docking/port training. B, Boxplots showing the durations of dissection, anastomosis, undocking/robot ...

Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial. Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib ...

Colorectal cancer (CRC) is the third most common and the second most lethal human cancer, with a worldwide incidence of nearly 2 million cases and close to 1 million deaths annually 1. Most CRCs arise ...

Oxaliplatin-induced portal hypertension in colorectal cancer: A systematic review of incidence, mechanisms, and predictive markers. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal ...